Acomplia could reach sales of $3 billion per year

Share this article:

Sanofi-Aventis' new obesity drug Acomplia could eventually generate sales of over $3 billion a year, its chairman told Reuters news service yesterday.
"I can tell you that for such a product, in my expectations, three (billion dollars) is not too much," Jean-Francois Dehecq said during a meeting of pharmaceutical executives in Brussels, commenting on forecasts for the medicine.
Sanofi-Aventis anticipates the launch of Acomplia, which also helps people quit smoking, to take place in the first part of 2006.
The drug is among the world's most anticipated since a global obesity epidemic threatens the health of millions of people in developed countries.

 

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.